Villumsen et al. performed a retrospective analysis of T2D patients with IBD, treatment of GLP-1-based therapies (GLP-1RAs and DPP4 inhibitors) lowered the risk of adverse clinical events related to IBD by 50% (Villumsen et al., 2021). This evidence concerns the gene DPP4 and inflammatory bowel disease.